Condition: Kidney Transplant Rejection · Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
The purpose of this study is to evaluate the safety and efficacy of carfilzomib and belatacept, administered with steroids and maintenance immunosuppression, in kidney transplant recipients with donor-specific antibody (DSA)-associated graft injury. Participants will be followed for 52 weeks after starting investigational therapy, including protocol biopsies at 3 months and 12 months after start of investigational therapy. The study will also assess changes in immune cell responses, blood and urine biomarkers, and biopsy-based pathomic features associated with antibody-mediated graft injury.
This description comes directly from the study's public registry record.
Yvonne Morrison, MS · 301-706-9137 · ymorrison@niaid.nih.gov
Always discuss trial participation with your own doctor first.
| University of Alabama Medical Center | Birmingham, Alabama, United States | Not Yet Recruiting |
| Mayo Clinic Arizona | Phoenix, Arizona, United States | Not Yet Recruiting |
| UCLA Medical Center (Site #: 71123) | Los Angeles, California, United States | Not Yet Recruiting |
| Northwestern University, Feinberg School of Medicine | Chicago, Illinois, United States | Not Yet Recruiting |
| Washington University | St Louis, Missouri, United States | Not Yet Recruiting |
| NYU Langone Health | New York, New York, United States | Recruiting |
| Duke University | Durham, North Carolina, United States | Not Yet Recruiting |
| University of Cincinnati | Cincinnati, Ohio, United States | Not Yet Recruiting |
| Cleveland Clinic | Cleveland, Ohio, United States | Not Yet Recruiting |
| University of Wisconsin - Madison | Madison, Wisconsin, United States | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06918990